Matthew L. Sherman
Oncologist and drug developer who led clinical programmes at Wyeth, including the sponsor side of the phase II temsirolimus (CCI-779) dose study in kidney cancer.
Executive Vice President and Chief Medical Officer, Deciphera Pharmaceuticals (since 2019) · earlier Chief Medical Officer, Acceleron Pharma, and Senior Vice President and Chief Medical Officer, Synta Pharmaceuticals · more than a decade at Wyeth-Ayerst Research / Genetics Institute · medical oncology fellowship, Dana-Farber Cancer Institute · MD, Dartmouth Medical School
Deciphera Pharmaceuticals (Waltham, Massachusetts, USA) ↗
Matthew Sherman was senior author, on the sponsor side at Wyeth, of the 2004 randomised phase II trial of temsirolimus (CCI-779) in advanced, previously treated kidney cancer (ATK2004). Patients received 25, 75 or 250 mg weekly; the response rate was 7% and neither efficacy nor toxicity differed clearly by dose, which supported the 25 mg dose used later. The trial had no control arm.
Sherman trained in chemistry at MIT, in medicine at Dartmouth, in internal medicine at Georgetown and in medical oncology at Dana-Farber, and held academic posts at Harvard Medical School. He spent more than ten years at Wyeth-Ayerst Research and Genetics Institute, where he also worked on the antibody-drug conjugate gemtuzumab ozogamicin for acute myeloid leukaemia, and later served as chief medical officer at Synta Pharmaceuticals, Acceleron Pharma and Deciphera Pharmaceuticals.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2004 | H | Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma ATK2004 Senior author (Wyeth): randomised phase II dose study of temsirolimus in refractory kidney cancer that supported the 25 mg weekly dose. |
Co-authors in the Atlas
People with a profile here who share at least one study with Matthew L. Sherman.
- Michael B. Atkins Medical oncologist specialising in kidney cancer and melanoma; led the randomised phase II dose study of temsirolimus (CCI-779) in advanced kidney cancer that supported taking the 25 mg weekly dose forward.
Every researcher with a profile →
Thank you. Your answer was counted anonymously.
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.